TRIAL TO ASSESS CHELATION THERAPY (TACT)

评估螯合疗法的试验 (TACT)

• 批准号: 7607465
• 负责人: PAMELA OUYANG
• 金额: $ 1.67万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607465
• 关键词: Alternative Therapies; Antioxidants; Cardiovascular system; Chelation Therapy; Clinical; Complementary and alternative medicine; Computer Retrieval of Information on Scientific Projects Database; Coronary heart disease; Dose; Economics; Edetic Acid; Event; Funding; Grant; Incidence; Institution; Life Style; Minerals; Morbidity - disease rate; Patients; Procedures; Purpose; Quality of life; Research; Research Personnel; Resources; Safety; Source; United States National Institutes of Health; Vitamins; chelation; drug modification; improved; mortality

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Coronary heart disease (CHD) is the leading cause of premature morbidity and mortality in the U.S.. Currently proven treatments for CHD include lifestyle modification, drugs, and procedures. Despite the availability of these treatments, many patients seek out and receive alternative therapies, including the complementary and alternative medicine (CAM) practice called chelation therapy. Chelation therapy involve IV administration of disodium ethylenediaminetetraacetic acid (EDTA), combined with high dose antioxidant vitamin and mineral supplements. Thus, clinical benefit from chelation therapy, if seen, could be due to EDTA, antioxidants, mineral supplements, or a combination of these. The purpose of this large scale 5-year multi-center trial is: 1) to determine whether chelation or high dose supplements in patients with CHD reduces the incidence of clinical cardiovascular events; 2) to determine whetner chelation and high-dose supplements have acceptable safety profiles; 3) To determine whether chelation or high-dose supplements improve the quality of life; 4) To conduct an economic analysis of chelation therapy and high dose supplements.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 冠心病（CHD）是美国过早发病率和死亡率的主要原因。 尽管有这些疗法的可用性，但许多患者仍寻求并接受替代疗法，包括称为螯合疗法的补充和替代医学（CAM）实践。 螯合疗法涉及静脉输送二钠乙二胺乙酸（EDTA），并结合高剂量的抗氧化剂维生素和矿物质补充剂。 因此，螯合疗法的临床益处（如果可以看见）可能是由于EDTA，抗氧化剂，矿物质补充剂或这些组合所致。 这项大规模5年多中心试验的目的是：1）确定冠心病患者的螯合或高剂量补充剂是否会降低临床心血管事件的发生率； 2）确定Whetner螯合和高剂量补充剂具有可接受的安全性； 3）确定螯合或高剂量补充剂是否改善了生活质量； 4）对螯合疗法和高剂量补充剂进行经济分析。